Responsibilities will include, but are not limited to, the following:
1. Developing and executing Hematology/Oncology HEOR research strategies to support patient access to Celgene products.
2. Conducting HEOR research on Celgene products leading to presentations at medical meetings and journal publications. Conduct prospective and retrospective observational studies, cost effectiveness research, comparative effectiveness research, chart reviews, registry trials, patient-reported outcomes research, meta-analyses and systematic reviews.
3. Manage outcomes research projects and investigator-initiated research proposals.
4. Assure compliance of evidence-based medicine and principles for economic assessment.
5. Design customer facing tools such reactive and proactive (FDAMA 114) presentations.
6. Developing and presenting HEOR studies to medical specialists at Market Access customers: Payers, Clinical Pathway companies, Federal, State, Group Purchasing Organizations, Pharmacy Benefit Managers, Clinical Pathways companies and other organized customers.

Qualifications
Prerequisite:
• M.S. in HEOR or related field, Ph.D. or Pharm.D. preferred
• A minimum of 3 years experience in outcomes research to support U.S. Market Access
• HEOR focused fellowship preferred.

Skills/Knowledge Required:
 Proficient in economic evaluation of healthcare
 Significant experience in analyzing claims databases and EMRs to assess the burden and cost of disease
 Knowledge of clinical and outcomes research applied to retrospective and prospective HEOR research
 Superior written and verbal communication skills with proficiency in communicating clinical technical information to varied internal and customer audiences
 Refined methodological, quantitative and analytical skills
 Strong track record in HEOR study methodology, statistics, data reporting and resource development
 High level strategic thinking, critical thinking, problem solving and decision making skills
 Experienced in influencing strategy with internal and external customer audiences
 Approximately 20% travel